Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease

Nature Neuroscience

Volumn 17, Issue 2, 2014, Pages 232-239

  Xiong, Wei ^a,b   Chen, Shao Rui ^c   He, Liming ^d   Cheng, Kejun ^e   Zhao, Yi Lin ^c   Chen, Hong ^c   Li, De Pei ^c   Homanics, Gregg E ^f   Peever, John ^g   Rice, Kenner C ^c   Wu, Ling Gang ^d   Pan, Hui Lin ^c   Zhang, Li ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; DEHYDROXYLCANNABIDIOL; GLYCINE; GLYCINE RECEPTOR; PRESYNAPTIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN STEM; CELL STRAIN HEK293; CONTROLLED STUDY; DEPOLARIZATION; GENOTYPE; HETEROZYGOTE; HYPEREKPLEXIA; MISSENSE MUTATION; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SPINAL CORD; SPINAL CORD DORSAL HORN; STARTLE REFLEX; SYNAPTOSOME; TACTILE STIMULATION; WILD TYPE;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; ANIMALS; BRAIN STEM; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HEK293 CELLS; HUMANS; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MUTATION; NEURONS; PRESYNAPTIC TERMINALS; RECEPTORS, GLYCINE; SODIUM CHANNEL BLOCKERS; SPINAL CORD; STIFF-PERSON SYNDROME; TETRODOTOXIN; VALINE;

EID: 84893778459     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3615     Document Type: Article

References (50)

1. Davidoff, R.A., Shank, R.P., Graham, L.T. Jr., Aprison, M.H. & Werman, R. Association of glycine with spinal interneurones. Nature 214, 680-681 (1967).
2. Betz, H. & Laube, B. Glycine receptors: recent insights into their structural organization and functional diversity. J. Neurochem. 97, 1600-1610 (2006).
3. Grudzinska, J. et al. The β subunit determines the ligand binding properties of synaptic glycine receptors. Neuron 45, 727-739 (2005).
4. Weltzien, F., Puller, C., O'Sullivan, G.A., Paarmann, I. & Betz, H. Distribution of the glycine receptor β-subunit in the mouse CNS as revealed by a novel monoclonal antibody. J. Comp. Neurol. 520, 3962-3981 (2012).
5. Lynch, J.W. & Callister, R.J. Glycine receptors: a new therapeutic target in pain pathways. Curr. Opin. Investig. Drugs 7, 48-53 (2006).
6. Turecek, R. & Trussell, L.O. Presynaptic glycine receptors enhance transmitter release at a mammalian central synapse. Nature 411, 587-590 (2001).
7. Jeong, H.-J., Jang, I.-S., Moorhouse, A.J. & Akaike, N. Activation of presynaptic glycine receptors facilitates glycine release from presynaptic terminals synapsing onto rat spinal sacral dorsal commissural nucleus neurons. J. Physiol. (Lond.) 550, 373-383 (2003).
8. Ye, J.-H. et al. Presynaptic glycine receptors on GABAergic terminals facilitate discharge of dopaminergic neurons in ventral tegmental area. J. Neurosci. 24, 8961-8974 (2004).
9. Hruskova, B. et al. Differential distribution of glycine receptor subtypes at the rat calyx of held synapse. J. Neurosci. 32, 17012-17024 (2012).
10. Shiang, R. et al. Mutations in the α1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat. Genet. 5, 351-358 (1993).
11. Harvey, R.J., Topf, M., Harvey, K. & Rees, M.I. The genetics of hyperekplexia: more than startle!. Trends Genet. 24, 439-447 (2008).
12. Bakker, M.J., van Dijk, J.G., van den Maagdenberg, A.M. & Tijssen, M.A. Startle syndromes. Lancet Neurol. 5, 513-524 (2006).
13. Davies, J.S. et al. The glycinergic system in human startle disease: a genetic screening approach. Front. Mol. Neurosci. 3, 8 (2010).
14. Becker, L. et al. Disease-specifc human glycine receptor α1 subunit causes hyperekplexia phenotype and impaired glycine-and GABA(A)-receptor transmission in transgenic mice. J. Neurosci. 22, 2505-2512 (2002).
15. Findlay, G.S. et al. Glycine receptor knock-in mice and hyperekplexia-like phenotypes: comparisons with the null mutant. J. Neurosci. 23, 8051-8059 (2003).
16. Blednov, Y.A., Benavidez, J.M., Homanics, G.E. & Harris, R.A. Behavioral characterization of knockin mice with mutations M287L and Q266I in the glycine receptor α1 subunit. J. Pharmacol. Exp. Ther. 340, 317-329 (2012).
17. Zhang, L. & Xiong, W. Nonpsychoactive cannabinoid action on 5-HT3 and glycine receptors. in Endocannabinoids: Actions at Non-CB1/CB2 Cannabinoid Receptors (eds. Abood, M.E., Sorensen, R.G. & Stella, N.) 199-218 (Springer, 2013).
18. Xiong, W. et al. Cannabinoids suppress infammatory and neuropathic pain by targeting α3 glycine receptors. J. Exp. Med. 209, 1121-1134 (2012).
19. Xiong, W. et al. Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. Nat. Chem. Biol. 7, 296-303 (2011).
20. Kehne, J.H., Gallager, D.W. & Davis, M. Strychnine: brainstem and spinal mediation of excitatory effects on acoustic startle. Eur. J. Pharmacol. 76, 177-186 (1981).
21. Pribilla, I., Takagi, T., Langosch, D., Bormann, J. & Betz, H. The atypical M2 segment of the β subunit confers picrotoxinin resistance to inhibitory glycine receptor channels. EMBO J. 11, 4305-4311 (1992).
22. Yang, Z., Cromer, B.A., Harvey, R.J., Parker, M.W. & Lynch, J.W. A proposed structural basis for picrotoxinin and picrotin binding in the glycine receptor pore. J. Neurochem. 103, 580-589 (2007).
23. Deleuze, C. et al. Structural difference between heteromeric somatic and homomeric axonal glycine receptors in the hypothalamo-neurohypophysial system. Neuroscience 135, 475-483 (2005).
24. Schneggenburger, R. & Forsythe, I.D. The calyx of Held. Cell Tissue Res. 326, 311-337 (2006).
25. Turecek, R. & Trussell, L.O. Reciprocal developmental regulation of presynaptic ionotropic receptors. Proc. Natl. Acad. Sci. USA 99, 13884-13889 (2002).
26. O'Shea, S.M., Becker, L., Weiher, H., Betz, H. & Laube, B. Propofol restores the function of "hyperekplexic" mutant glycine receptors in Xenopus oocytes and mice. J. Neurosci. 24, 2322-2327 (2004).
27. Shan, Q., Han, L. & Lynch, J.W. Function of hyperekplexia-causing α1R271Q/L glycine receptors is restored by shifting the affected residue out of the allosteric signalling pathway. Br. J. Pharmacol. 165, 2113-2123 (2012).
28. Lape, R., Plested, A.J., Moroni, M., Colquhoun, D. & Sivilotti, L.G. The α1K276E startle disease mutation reveals multiple intermediate states in the gating of glycine receptors. J. Neurosci. 32, 1336-1352 (2012).
29. Harvey, R.J. et al. GlyR α3: an essential target for spinal PGE2-mediated infammatory pain sensitization. Science 304, 884-887 (2004).
30. - cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J. Biol. Chem. 287, 33853-33864 (2012).
31. Andermann, F., Keene, D.L., Andermann, E. & Quesney, L.F. Startle disease or hyperekplexia: further delineation of the syndrome. Brain 103, 985-997 (1980).
32. Zhou, L., Chillag, K.L. & Nigro, M.A. Hyperekplexia: a treatable neurogenetic disease. Brain Dev. 24, 669-674 (2002).
33. Praveen, V., Patole, S.K. & Whitehall, J.S. Hyperekplexia in neonates. Postgrad. Med. J. 77, 570-572 (2001).
34. Rees, M.I. et al. Hyperekplexia associated with compound heterozygote mutations in the β-subunit of the human inhibitory glycine receptor (GLRB). Hum. Mol. Genet. 11, 853-860 (2002).
35. Chung, S.K. et al. GLRB is the third major gene of effect in hyperekplexia. Hum. Mol. Genet. 22, 927-940 (2013); erratum 22, 2552 (2013).
36. Rees, M.I. et al. Mutations in the gene encoding GlyT2 (SLC6A5) defne a presynaptic component of human startle disease. Nat. Genet. 38, 801-806 (2006).
37. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515-527 (2009).
38. Ashton, H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 48, 25-40 (1994).
39. Tijssen, M.A. et al. The effects of clonazepam and vigabatrin in hyperekplexia. J. Neurol. Sci. 149, 63-67 (1997).
40. Borghese, C.M. et al. Characterization of two mutations, M287L and Q266I, in the α1 glycine receptor subunit that modify sensitivity to alcohols. J. Pharmacol. Exp. Ther. 340, 304-316 (2012).
41. Kung, A.Y., Rick, C., O'Shea, S., Harrison, N.L. & McGehee, D.S. Expression of glycine receptors in rat sensory neurons vs. HEK293 cells yields different functional properties. Neurosci. Lett. 309, 202-206 (2001).
42. A and glycine receptor-mediated synaptic currents in brain stem motoneurons. J. Neurophysiol. 90, 870-875 (2003).
43. Chau, P., Hoifodt-Lido, H., Lof, E., Soderpalm, B. & Ericson, M. Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate. Alcohol. Clin. Exp. Res. 34, 39-45 (2010).
44. Li, J. et al. Microinjection of glycine into the ventral tegmental area selectively decreases ethanol consumption. J. Pharmacol. Exp. Ther. 341, 196-204 (2012).
45. Findlay, G.S. et al. Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice. J. Pharmacol. Exp. Ther. 300, 526-534 (2002).
46. Hu, X.-Q., Sun, H., Peoples, R.W., Hong, R. & Zhang, L. An interaction involving an arginine residue in the cytoplasmic domain of the 5-HT3A receptor contributes to receptor desensitization mechanism. J. Biol. Chem. 281, 21781-21788 (2006).
47. Pan, Y.Z. & Pan, H.L. Primary afferent stimulation differentially potentiates excitatory and inhibitory inputs to spinal lamina II outer and inner neurons. J. Neurophysiol. 91, 2413-2421 (2004).
48. Zhou, H.Y., Zhang, H.M., Chen, S.R. & Pan, H.L. Increased C-fber nociceptive input potentiates inhibitory glycinergic transmission in the spinal dorsal horn. J. Pharmacol. Exp. Ther. 324, 1000-1010 (2008).
49. Helmchen, F., Borst, J.G. & Sakmann, B. Calcium dynamics associated with a single action potential in a CNS presynaptic terminal. Biophys. J. 72, 1458-1471 (1997).
50. Xiong, W., Wu, X., Lovinger, D.M. & Zhang, L. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors. J. Neurosci. 32, 5200-5208 (2012); erratum 32, 12979 (2012).